Vor has license agreements with Columbia University, the National Institutes of Health, and Editas Medicine for ex-vivo Cas9 gene-edited hematopoietic stem cell therapies. The company recently announced a strategic shift, winding down operations and exploring options to maximize shareholder value.
Cyborg Score Rationale
Vor reported a net loss of $32.5 million in Q1 2025 with an accumulated deficit of $489.5 million since inception. The company is winding down operations and exploring strategic alternatives.
Top Insights
Lead program trem-cel combines engineered hematopoietic stem cells with VCAR33 CAR-T therapy for AML treatment.
R&D expenses increased to $26.7 million in Q1 2025 driven by higher clinical trial costs for trem-cel and VCAR33.
Strategic investors include Johnson & Johnson InnovationJJDC and Novartis Institutes for BioMedical Research.
Recent challenges have led to significant restructuring with focus shifted toward exploring strategic alternatives.
Named Competitors
CAR-T Immunotherapy — Engineered T-cell therapies for hematologic malignancies
Engineered Cell Therapy — Autologous engineered cell therapies for cancer
Cancer Immunotherapy — Multispecific biologics for cancer treatment
Recent Developments
(Q1 2025) Accumulated deficit reached $489.5 million; R&D expenses grew to $26.7 million
(2025) Company announced strategic shift, winding down operations and exploring strategic alternatives
(December 2025) ISS Governance QualityScore rated 10
Open the full interactive Vor Biopharma Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.